158
РАЗРАБОТКА И РЕГИСТРАЦИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ. 2022. Т. 11, № 1
DRUG DEVELOPMENT & REGISTRATION. 2022. V. 11, No. 1
REFERENCES
1.
Ob utverzhdenii Pravil nadlezhashchey proizvodstvennoy praktiki:
Prikaz Minpromtorga Rossii ot 14.06.2013g. № 916 (s izmeneniyami
na 18.12.2015 g.): zaregistrirovano v Minyuste Rossii 10.09.2013
№ 29938
[On the approval of the
Rules of Good Manufacturing
Practice: Order of the Ministry of Industry and Trade of Russia
dated 14.06.2013 No 916 (as amended on December 18, 2015):
registered with the Ministry of Justice of Russia on September 10,
2013 No. 29938]. Available at: http://www.consultant.ru. Accessed:
18.08.2021. (In Russ.)
2. Podpruznikov Yu. V., Shestakov V. N. Review, characteristics and
analysis of the last changes in the GMP requirements.
Razrabotka
i registratsiya lekarstvennykh sredstv
=
Drug development & registra-
tion
. 2016;(3):202–218. (In Russ.)
3.
Ob utverzhdenii Pravil nadlezhashchey proizvodstvennoy praktiki
Evraziyskogo ekonomicheskogo soyuza: Reshenie Soveta Evraziyskoy
ekonomicheskoy komissii ot 03.11.2016 № 77
[On approval of the
Rules of Good Manufacturing Practice
of the Eurasian Economic
Union: Decision of the Council of the Eurasian Economic
Commission dated 03.11.2016 No 77]. Available at: http://www.
consultant.ru. Accessed: 18.08.2021. (In Russ.)
4. EudraLex Volume 4 EU Guidelines for Good Manufacturing
Practice for Medicinal Products for Human and Veterinary Use.
2015. Available at: https://ec.europa.eu/health/documents/
eudralex/vol-4_en. Accessed: 18.08.2021.
5. Sargent E. V., Flueckiger A., Lovsin Barle E., Luo W., Molnar L. R.,
Sandhu R., Weideman P. A. The Regulatory Framework for Preven-
ting Cross-Contamination of Pharmaceutical Products: History
and Considerations for the Future.
Regulatory Toxicology and Phar-
macology: RTP
. 2016;79(1):S3–S10. DOI: 10.1016/j.yrtph.2016.05.029.
6. ICH guideline Q9 on quality risk management: EMA/CHMP/
ICH/24235/2006 – 2015. Available at: https://ich.org/page/quality-
guidelines. Accessed: 18.08.2021.
7.
Prikaz Minpromtorga Rossii ot 12.12.2013 № 1997 "Ob utverzhdenii
Rekomendatsiy po organizatsii proizvodstva i kontrolya kachestva
lekarstvennykh sredstv"
[Order of the
Ministry of Industry and
Trade of Russia dated December 12, 2013 No. 1997 "On approval
of the Recommendations for the organization of production and
quality control of medicines"]. Available at: http://www.consultant.
ru. Accessed: 18.08.2021. (In Russ.)
8. ISPE Baseline® Guide: Volume 7 – Risk-Based Manufacture of Phar-
maceutical Products (Risk-MaPP). Makati: International Society for
Pharmaceutical
Engineering; 2017. 178 p.
9. How safe is your process? The usual causes of pharmaceutical
contamination. Pharmaceutical Technology. 2018. Available at:
https://www.pharmaceutical-technology.com/powder-handling/
causes-of-pharmaceutical-contamination. Accessed: 15.09.2021.
10. ICH guideline Q10 on pharmaceutical quality system EMA/CHMP/
ICH/214732/2007
–
2008. Available at: https://ich.org/page/
quality-guidelines. Accessed: 18.08.2021.
11. Spiridonova A. A., Khomutova E. G. The risk-oriented approach
in the quality management system of an industrial enterprise:
the problem of selecting the methods of risk management.
Organizator proizvodstva
=
Organizer of Production.
(In Russ.)
2017;25(2):92–100. DOI: 10.25065/1810-4894-2017-25-2-92-100.
12.
GOST R 58771-2019 "Menedzhment riska. Tekhnologii otsenki riska"
[GOST R 58771-2019 "Risk management.
Risk Assessment Techno-
logies"]. Moscow: Standartinform; 2020.146 p. (In Russ.)
13. Spiridonova A. A., Rudakova V. A., Khomutova E. G. Quality risk
management of immunobiological
drug production under culti-
vation conditions.
Biofarmatsevticheskiy zhurnal
=
Russian Journal
of Biopharmaceuticals
. 2019;11(4):54–60. (In Russ.) DOI: 10.17513/
np.407.
14. Inspection of health based exposure limit (HBEL) assessments
and use in quality risk management: AIDE-memoire PI 052-1.
Secretariat of the Pharmaceutical Inspection Convention. 2020.
Available at: http://www.picscheme.org. Accessed: 08.08.2021.
Достарыңызбен бөлісу: